Welcome to our dedicated page for VIVOS SEC filings (Ticker: RDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vivos Inc. filings document formal disclosures for a radiotherapeutic company developing RadioGel® for human applications and IsoPet® for veterinary use. The company’s 8-K reports record material definitive agreements, executive appointments, compensatory arrangements, and governance changes tied to its operating structure.
Regulatory filings also frame RDGL’s public-company disclosures around capital structure, shareholder voting matters, clinical and regulatory updates, and operating and financial results. These records provide the formal context for the company’s radionuclide therapy programs, manufacturing and development activities, and corporate governance matters.
Vivos Inc. (RDGL) reported limited commercial activity and continuing losses for the six months ended June 30, 2026. Revenue was $72,468, primarily from IsoPet® product and related items, but cost of goods sold exceeded revenue, resulting in a gross loss. Operating expenses of $1.19 million produced an operating loss of $1.20 million, and after a $847,628 loss on share and warrant exchanges, the net loss reached $2,015,034.
Cash increased to $2,336,022, driven by $2,203,800 raised via Regulation A+ equity offerings and associated warrants, while total liabilities remained low at $123,955. The company has an accumulated deficit of $90.4 million and discloses that current cash is insufficient for its plans, estimating a need for about $3.0 million per year and $9.0 million over the next 36 months to fund operations and clinical development.
Management states there is substantial doubt about the ability to continue as a going concern absent additional capital. Strategically, Vivos highlights progress in its Precision Radionuclide Therapy™ platform, including FDA Breakthrough Device status, approval of an Early Feasibility IDE in July 2026 for a first-in-human study at Mayo Clinic, expansion of its IsoPet® animal-therapy network, and the consolidation of Vivos Scientific India LLP as a variable interest entity to support international clinical and manufacturing activities.
VIVOS INC President Brad Allan Weeks purchased 50,000 shares of Common Stock on 2026-08-10 at $0.0548 per share in an open market or private transaction. Following this purchase, he directly holds 1,521,654 shares of VIVOS INC Common Stock.
VIVOS INC CEO and President Michael K. Korenko purchased 150,000 shares of Common Stock on 2026-08-10 in a transaction classified as a purchase in an open market or private transaction. The shares were acquired at a price of $0.0531 per share, bringing his directly held stake to 11,435,090 shares after the transaction.
VIVOS INC President Brad Allan Weeks reported open-market purchases of company common stock. He bought 60,000 shares on July 21, 2026 and 32,000 shares on July 22, 2026, each at $0.05 per share, for a total of 92,000 shares acquired directly.
VIVOS INC President Brad Allan Weeks reported multiple acquisitions of Common Stock. He made open-market purchases totaling 60,000 shares on July 9–10, 2026 at $0.0800 per share and received stock grants totaling 247,270 shares in March and June 2026. Following these transactions, he directly owns 1,379,654 shares.
Vivos Inc CEO and President Michael K. Korenko reported an open-market purchase of 200,000 shares of common stock at $0.0571 per share on July 15, 2026. Following this transaction, he directly holds 11,285,090 shares of Vivos Inc common stock.
VIVOS INC President Brad Allan Weeks reported open-market purchases of company Common Stock. He bought 48,000 shares on July 9, 2026 and 12,000 shares on July 10, 2026, both at $0.08 per share. After these transactions, he directly holds 999,235 shares of Common Stock.
Vivos Inc. reported a larger quarterly loss while modestly growing early revenue as it develops its radionuclide cancer therapies. For the three months ended March 31, 2026, revenue was $36,068, up from $26,748, mainly from IsoPet® animal treatments and related products.
The company recorded a net loss of $1,184,845 versus $834,696 a year earlier, driven by operating expenses and a $651,628 loss on a warrant exchange. Cash was $2,525,782 with negative operating cash flow of $429,861. Management states there is substantial doubt about Vivos’ ability to continue as a going concern and estimates it needs about $3.0 million per year, or $9.0 million over 36 months, to fund planned activities.
To address this, Vivos continues to raise capital under its qualified Regulation A+ offerings, including new shares and warrants sold in March and April 2026. The company is advancing its IsoPet® veterinary business, pursuing FDA approval for RadioGel® human use, and building U.S. and Indian manufacturing and clinical infrastructure.
Vivos Inc CEO and President Michael K. Korenko, who also serves as a director, reported an open-market purchase of common stock. On May 11, 2026, he bought 150,000 shares of Vivos Inc common stock at $0.0618 per share. Following this transaction, his direct ownership increased to 11,085,090 common shares, indicating a modest addition to an already large personal stake in the company.
Vivos Inc